Senti Biosciences Inc
Company Profile
Business description
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Contact
2 Corporate Drive
First Floor
South San FranciscoCA94080
USAT: +1 650 239-2030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
48
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,688.00 | 35.50 | -0.41% |
| CAC 40 | 7,589.33 | 0.33 | -0.00% |
| DAX 40 | 23,356.71 | 6.16 | 0.03% |
| Dow JONES (US) | 42,206.82 | 35.16 | 0.08% |
| FTSE 100 | 8,781.63 | 6.98 | 0.08% |
| HKSE | 23,689.13 | 158.65 | 0.67% |
| NASDAQ | 19,447.41 | 98.86 | -0.51% |
| Nikkei 225 | 38,354.09 | 49.14 | -0.13% |
| NZX 50 Index | 12,532.65 | 36.40 | -0.29% |
| S&P 500 | 5,967.84 | 13.03 | -0.22% |
| S&P/ASX 200 | 8,474.90 | 30.60 | -0.36% |
| SSE Composite Index | 3,381.58 | 21.69 | 0.65% |